Whitepaper
Stereoscopic 3-D digital imaging holds the promise of improving the detection, diagnosis, and treatment of disease as well as enhancing the training and preparation of medical professionals through use of stereoscopic 3-D displays in concert with the many volumetric visualization techniques/modalities developed in recent years.
You can find the link at www.planar3d.com/whitepapers
Image Files
|
|
|
|
Download Low-Res Hi-Res |
Download Low-Res Hi-Res |
 |
|
| Planar’s SD2250 in use for diagnosing breast cancer. | |
FAQ for Planar Digital Mammography
Download PDF
What organizations conducted the study?
The study is being administered by BBN Technologies of Cambridge MA. The clinical trial is being conducted at the Emory University Breast Clinic in Atlanta GA. Key participants in the study are:
David J. Getty, Ph.D., Principal Investigator for the study and Division Scientist at BBN Technologies of Cambridge, Massachusetts
Dr. Carl D’Orsi, M.D., The Emory Clinic, Professor of Radiology, Director, Division of Breast Imaging
Where are the results from the study being presented?
The results of the study are being presented at the annual meeting of the Radiological Society of North America (RSNA) in Chicago. The date of the presentation was Tuesday November 27. There was a press conference at RSNA regarding the study on Wednesday the 28th.
Why are the results of the study important?
Use of the stereoscopic 3D workstation incorporating Planar’s StereoMirror™ prototype monitor in the study resulted in a significant reduction in both the number of false positives and false negative findings for breast cancer. A false positive finding is a diagnostic result that is found to be incorrect in a subsequent exam while a false negative is a situation where a potentially cancerous lesion is not detected.
These results indicate the potential to dramatically improve the accuracy of breast cancer screening and with it the possibility of large gains in the cost effectiveness of breast cancer screening ? earlier cancer detection from improved sensitivity, and potentially large savings in the costs, both financial and human, of the many cases now recalled unnecessarily for diagnostic work-up.
How was Planar involved?
Planar Systems contributed 5-megapixel stereoscopic 3D prototype monitors based on Planar’s StereoMirror technology for use in this study. These displays use the same stereoscopic 3D technology available in the entire Planar StereoMirror product line and illustrate the flexibility of this approach to stereoscopic 3D displays.
Why was Planar selected to provide displays for this study?
Planar has almost 25 years of experience creating displays for specialty applications. It has a proven reputation for innovation and reliability. Planar has numerous FDA-certified displays and its unique StereoMirror displays provided industry-leading 3D/stereoscopic viewing performance and comfort.
What is it about the StereoMirror that made it the preferred solution for this study?
Planar’s StereoMirror is widely recognized for providing the best performance available in a stereoscopic solution. Superb stereoscopic 3D viewing performance is critical to the effectiveness of the diagnosis. The StereoMirror is also the preferred choice for professional applications that require long sessions with stereoscopic imagery. Autostereo solutions rely on flickering to create a 3D effect, while the StereoMirror is flicker-free, reducing headaches and other side effects. More details comparing the StereoMirror to 3D/stereoscopic alternatives can be found at http://www.planar3d.com/3d-technology/3d-technologies/.
What is the difference between a 2-D and 3-D mammogram?
In standard 2D mammography subtle lesions may be masked by underlying or overlying normal tissue and thus be missed. Also, normal tissue scattered at different depths can align so as to mimic a lesion. This can have appearance of diseased tissue, thus leading to a false-positive finding. In a stereoscopic digital mammogram (3D) two digital x-ray images of the breast acquired from two different points of view separated by about ten degrees. This allows the radiologist to directly see the internal structure of the breast in three dimensions.
How else can the StereoMirror be used in medical applications?
There are a wide variety of additional potential medical applications for Planar’s StereoMirror™. These include:
- Teaching anatomy
- Treatment planning
- Surgical simulation
- Minimally invasive surgery (FDA certification needed)
- Diagnosis using CT, MRI, PET, Ultrasound (FDA certification needed)
- Diagnosis of diabetic retinopathy and other ophthalmic use
- Design of new drugs (molecular modeling)
What other applications are using the StereoMirror?
The Planar StereoMirror is used for a variety of applications that require stereoscopic visualization to effectively interpret and respond to data. Example applications include:
- Geospatial
- Oil & gas exploration
- Crystallography and molecular modeling
- Mechanical design
- Simulation & training
- PC video gaming
When will the results of the study be published?
The researchers involved in this study are working to publish the results in the future. The target publication is not currently available.
What other displays does Planar make for medical applications?
Planar has been making FDA-certified displays for many years. In addition, the company’s Industrial Business Unit develops and manufactures embedded displays for numerous medical devices, including patient monitors and defibrillators.
How long has Planar been making displays for digital mammography?
Planar acquired Dome Imaging in 2002. Prior to the acquisition, Dome had been working developing and manufacturing solutions for digital mammography for many years.
Where can I find more information about Planar’s StereoMirror or Z16?
www.planar3d.com includes numerous resources about the StereoMirror, including configuration, applications and comparisons of 3D/stereoscopic technologies.
www.planarmedical.com/ includes resources related to Planar’s diagnostic imaging displays, including the recently announced Z16. Check back at this page for additional updates.
Receive our Email Newsletter
Subscribe to our newsletter and receive updates on our new product lines, technology breakthroughs and more.